Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine in Dementia with Lewy Bodies

Cognition Therapeutics completed a Type C meeting with the FDA to discuss plans for a proposed Phase 2b study of zervimesine in dementia with Lewy bodies. The FDA reviewed clinically meaningful endpoints for the next study, and Cognition is awaiting meeting minutes. Zervimesine is an investigational drug for CNS diseases such as Alzheimer's and DLB, and has been shown to interrupt toxic effects of Aβ and ɑ-synuclein. The company believes the drug can regulate pathways impaired in these diseases through its interaction with the sigma-2 receptor.